化合物EED226 T3458

Product Introduction
Bioactivity


英文名: EED226

描述: EED226 是多梳抑制复合物 2 抑制剂，是一种有效的、选择性的、可口服的胚胎外胚层发育 (EED) 抑制剂，IC50 为 22 nM，具有强抗肿瘤活性。当 H3K27me0 肽用作体外酶法测定的底物时，它抑制 PRC2的 IC50为 23.4 nM。

细胞实验: G401 cells are treated with EED226 for 3 d at the indicated concentrations. Total histone H3 is shown as a loading control. WB analysis for protein expression of H3K27me3, H3K27me2, H3K27me1. (Only for Reference)

体外活性: EED226 induces a conformational change upon binding EED, leading to loss of PRC2 activity. EED226 also effectively inhibits PRC2 containing a mutant EZH2 protein resistant to SAM-competitive inhibitors. It regulates histone H3K27 methylation and PRC2 target gene expression in cells. In the in vitro enzymatic assays, EED226 inhibits PRC2 with an IC50 (half-maximal inhibitory concentration) of 23.4 nM when the H3K27me0 peptide is used as substrate and an IC50 of 53.5 nM when the mononucleosome is used as the substrate, with the stimulatory H3K27me3 added at 1 × Kact (1.0 μM). EED226 is noncompetitive with both SAM and peptide substrate. EED226 bound to EED and PRC2 complex with a 1:1 stoichiometry and Kd of 82 nM and 114 nM, respectively. EED226 does not disrupt the PRC2 complex and could still occupy its binding pocket with a SAM-competitive EZH2 inhibitor bound to PRC2. EED226 shows remarkable selectivity for PRC2 complex over 21 other protein methyltransferases, kinases and other protein classes, The only other histone methyltransferase that can be inhibited by EED226 is the EZH1-PRC2 complex. EED226 with moderate permeability leads to a dose-dependent decrease of both global H3K27me3 and H3K27me2 markers in G401 cell[1].

体内活性: EED226 effectively induces tumor regression in a mouse xenograft model. EED226 in a solid dispersion formulation are well tolerated in animals. EED226 clearly demonstrates a dose-dependent efficacy in the mouse xenograph study[1]. EED226 inhibits the growth of diffuse large B-cell lymphoma (DLBCL) xenografts and reduces H3K27me3 levels to a similar extent as an EZH2 inhibitor[2]. EED226 has very low in vivo and in vitro clearance and approximately 100% oral bioavailability, low volume of distribution (0.8 L/kg), reasonable terminal t1/2 (2.2 h), and moderate plasma protein binding (PPB)(14.4%). Its solubility is relatively low and with little dependency on the pH of the medium[3].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 68 mg/mL (184.1 mM)


关键字: inhibit | antitumor | EED 226 | Inhibitor | PRC2 | EED | EED226 | K27me3 | EED-226 | Histone Methyltransferase

相关产品: UNC0379 | ZLD1039 | UNC0321 | SETDB1-TTD-IN-1 | EEDi-5285 | MAK683 | TNG-462 | CARM1-IN-1 | XY1 | MS37452

相关库: Anti-Aging Compound Library | Anti-Cancer Compound Library | Epigenetics Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | Orally Active Compound Library | Histone Modification Compound Library | NO PAINS Compound Library | Bioactive Compound Library | Chromatin Modification Compound Library

化合物EED226 T3458信息由TargetMol中国为您提供，如您想了解更多关于化合物EED226 T3458报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途